full list rate price target
earn chang report pleas see
tabl page
mani swing factor favor
expect healthi end market trend continu drive tool dx growth
import quarterli read view barclay global healthcar
confer march came away greater convict strength would
continu without budget flush hangov biopharma expect trend remain
strong favor fund push toward special therapeut
stabl cancel sponsor consolid far improv near-term visibl
industri global macro trend remain healthi bode well near-term end market
perform trade war discuss remain topic coverag limit
direct exposur given long-cycl natur end market believ macro
import watch trend vs near-term healthcar
implement pama top mind though channel check suggest
impact pace lab consolid yet final academ end market
recent improv nih outlook bode well purchas sentiment
said number put take mind strong flu
season bode well diagnost manufactur obviou beneficiari
pre-announc flu million season product modest tailwind
thermo fisher well unusu sever weather could weigh volum growth
lab labcorp quest embed conservat forecast
magnitud inclement weather clearli greater expect
time vs creat quarterli headwind
implement could creat volatil quarterli
variabl reimburs expens pass-through revenu add new layer headlin
volatil recommend read underli servic revenu final
sentiment high coverag favor invest avenu within
healthcar cover julian mitchel rais bar life scienc
tool peer pre-announc quarterli beat earli march
term stock believ thermo fisher carri signific momentum
see upsid guidanc organ acquir growth
manag guid organ growth cours
follow organ growth best result among peer posit
near-term
momentum fundament thermo fisher benefit uniqu capabl
biopharma across bioproduct clinic trial logist recent acquir
patheon busi macro datapoint suggest industri end market remain
healthi provid anoth lever growth final strong flu season benefit
growth season product margin ad convers
earli time headwind coverag reflect guidanc
acquir growth remain bullish patheon acquisit see long runway
ahead thermo fisher aggreg share wallet biopharma custom
reiter ow rate recommend share high-qual avenu gain
exposur theme innov healthcar
action lower forecast labcorp lh quest due weather
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
laboratori corp america hldg lh
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
mark calendar tool time industri expert confer call seri
stock price perform valuat
expect healthi end market trend continu drive tool dx growth
import quarterli read view barclay global healthcar confer
march came away greater convict strength would continu
without budget flush hangov biopharma expect trend remain strong
favor fund push toward special therapeut stabl cancel
sponsor consolid far improv near-term visibl industri global macro
trend remain healthi bode well near-term end market perform trade
war discuss remain topic coverag limit direct exposur given long-
cycl natur end market believ macro import watch
trend vs near-term healthcar implement pama top mind
though channel check suggest impact pace lab consolid
yet final academ end market recent improv nih outlook bode well
end market coverag grow parallel
said number put take mind strong flu
season bode well diagnost manufactur obviou beneficiari pre-
announc flu million season product modest tailwind thermo
fisher well unusu sever weather could weigh volum growth lab
labcorp quest embed conservat forecast magnitud
inclement weather clearli greater expect time
vs creat quarterli headwind implement
could creat volatil quarterli variabl reimburs expens pass-
revenu add new layer headlin volatil recommend read
underli servic revenu final sentiment high coverag
favor invest avenu within healthcar cover julian mitchel
rais bar life scienc tool peer pre-announc quarterli beat earli
lower forecast labcorp quest relat inclement weather
compani model volum headwind weather
vs previous model headwind annual forecast compani
beyond unchang assum lost volum made later
year
labcorp lh lower ep forecast
revenu billion vs billion continu forecast billion
full-year revenu adj ep
quest lower ep forecast
revenu billion vs billion continu forecast billion
full-year revenu adj ep
report includ focus look metric matter earn season
includ one-pag overview compani coverag thought
estim septemb quarter well set-up full-year guidanc
full thought end market environ pleas see follow report
barclay global healthcar confer review life scienc tool
diagnost end market op hot miami
biopharma end market biopharma end market tracker budget
flush consolid debat miami beach
industri end ket barclay tool industri tracker pmi
dx/lab end market lab trend system go labcorp view
guid conserv lab novemb employ trend
mark calendar tool time industri expert
pleas see announc full detail tool time
 industri expert confer call seri tool dx
pleas join us tool time seri industri expert confer call span
breadth coverag includ life scienc tool diagnost clinic lab
call focu sever top debat coverag featur
dialogu top industri expert specif seri includ kol discuss
life scienc tool categori bioproduct gener sequenc cro
trend earli develop perspect lab director ob/gyn oncologist
psychiatrist plastic surgeon dermatologist use diagnost healthcar
devic time avail end call investor hope
join us
et bioproduct industri updat post-interphex
et medic aesthet industri updat post-asap
et lab director perspect clinic lab dx post-war
et gener sequenc view broad institut
et psychiatrist view myriad genesight assay post-apa annual
et earli develop industri updat note call
et ob/gyn perspect diagnost gyn surgic medic
et oncologist perspect cancer diagnost post-asco
dial-in detail everi confer call
note iqvia health syneo health repres ep figur adjust inc stock comp
stock price perform valuat
stock perform present price
enterpris valu life scienc tool compani trade near twelv
month ntm ebitda estim compar five year averag ntm
ebitda ten year averag ntm ebitda past five year group
broadli trade within rang forward ebitda enterpris valu
diagnost compani trade near twelv month ntm ebitda
estim compar five-year averag ntm ebitda ten-year
averag ntm ebitda past five year group broadli trade within
rang forward ebitda enterpris valu cro compani
trade near twelv month ntm ebitda estim compar five-year
averag ntm ebitda ten-year averag ntm ebitda past
five year group broadli trade within rang forward ebitda
enterpris valu lab compani trade near twelv month ntm
ebitda estim compar five-year averag ntm ebitda ten-
year averag ntm ebitda past five year group broadli trade
within rang forward ebitda
thought agil
barclay
report
op hot miami
believ posit end market fundament across biopharma chemic
import takeaway watch agil earn
caution recent tuck-in could lead potenti initi dilut off-set
earn upsid clear benefit beyond year biopharma agil healthi lc
order backlog bode well achiev msd biopharma growth chemic
 upsid estim growth could serv import lever
compani model growth biopharma growth
chemic furthermor new product begin reson
market drive better revenu growth margin expans compani
specif believ ultivo intuvo replac cycl drive
revenu upsid annual next sever year agil close two notabl tuck-in
acquisit quarter million aati lasergen
depend expect revenu ramp aati collect could
dilut ep note origin million lasergen invest march
dilut believ best yet come
reson commerci strategi coupl compel cascad new product
launch set multipl year premium top bottom line growth
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancechem energi growthc agil rev continu see improv variou industri datapoint importantli compani see reinvest chemic segment revenu well refin explor segment grown doubl digit last four quarter compani rais guidanc segment expect momentum sustain least next two quarter new gc product cycl intuvo repres multi-year biotech growthbiopharma agil largest end market rev expect growth moder tougher comp growth growth growth tie lc lsag agil crosslab see sustain tailwind growth broad base compani see strength larg molecul manufactur growthour forecast emb organ growth lsag dgg agil crosslab forecast emb organ growth lsag dgg fx guidanc assum rate agil use fx hedg euro pound yen mitig ep op marginagil see opportun push margin higher time driven continu improv well increment margin leverag top line growth believ agil guidanc screen reason guidanc adj ebit margin guidanc assum ep growth mm cffo estim repres y/i growth mm capital-expenditure forecast includ roughli complet compani new nucleic acid mm agil plan return dividend increas compani commit two tranch buyback tranch maintain dilut share second tranch statementcash barclay life scienc tool diagnost
overweight agil built strong track
record reput oper perform
develop divers portfolio busi
across instrument diagnost favor
agil exposur growth biopharma
rev new product cycl ga chromatographi
opportun repatri drive upsid
improv growth chemic energi end
market due stabil trend gc product
cycl could lead better growth capit alloc
also remain opportun upsid case
reflect upsid ebitda billion
agil exposur econom activ end
market could impact growth downsid
case reflect downsid ebitda
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
commentari around order end market trend import
result quarter histor limit visibl financi
given depend capit sale remind return organ
growth includ beat estim encourag
beat primarili driven organ upsid continu strength nano solid
trend calid mass spectrometri addit compani guid
healthi level margin expans furthermor european academ order
trend continu improv manag tone around new product initi
bode well said model organ growth y/i deceler
versu given robust end market environ look better
visibl compani turn corner organ growth
consist mid-singl digit growth closer peer reiter equal
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidanceeuropean academ end market commentaryapproxim revenu gener academ custom revenu europ suggest european market stabil return long-term lsd-msd growth importantli believ improv european fund environ normal trend though market remain soft certain countri n/an/an/an/aorgan growthdespit easi comp expect organ growth moder follow strong result embed guidanc expect improv bsi partial off-set lsd declin revenu activ compani continu look complementari asset offer better solut custom said expect continu similar pace previou quarter build impact margin adj compani expect realiz oper margin expans compani target margin expans per year averag specif compani note growth portion portfolio rev gross oper margin excess compani averag forecast margin expans rate expect tax rate remain usual ep year expect back half weight mm capital-expenditure guidanc million repres increas mm expect continu pay dividend may announc million share repurchas author compani complet roughli repurchas said build repurchas estim guidanc assum around million share outstand statementcash barclay life scienc tool diagnost
equal weight view thesi
balanc biggest turnaround
stori life scienc tool coverag
begin see earli sign better sale
manag system drive higher earn
compani said revenu visibl
weaken remain cautiou around
execut success
expect aid new manag system
support fund environ appli
ebitda multipl upsid ebitda
million yield upsid case
execut issu fund capit purchas
drive downsid ebitda forecast
case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
thought charl
river barclay
report
op hot miami
healthi fund environ biotech believ charl river good
foot go recent close mpi research acquisit focu
embed forecast start specif updat expand revenu
compani site michigan discoveri safeti assess dsa
busi expect continu high-singl digit organ growth driven primarili
safeti assess busi posit discoveri busi stabil recent
commentari suggest busi grow view addit financi
benefit acquisit mpi research improv crl competit posit safeti
assess manufactur segment expect continu strength double-
digit growth driven microbi biolog busi said believ
model organ growth long-term trend like impact capac
constraint compani biolog busi research model servic rm
expect low-singl digit organ growth move forward china research model
servic offset declin research model revenu develop region charl river
new rm facil shanghai ship
et thursday may commentarybarcguidancebarcguidancerm organ growthrm view low-single-digit grower long-term growth china servic expect off-set weaker demand research model develop region compani new rm facil shanghai ship help re-acceler growth growthdsa organ growthdsa expect high-single-digit grower long-term safeti assess rfp activ book strong improv set go capac remain optim level led price increas discoveri solid demand small-to mid-siz biopharma compani improv outlook believ announc acquisit mpi research improv compani competit posit rang organ manufactur organica lt double-digit grower driven microbi solut biolog busi biolog growth expect moder capac brought on-line meet demand growthtot organ growth organ growth impact capac constraint compani biolog busi addit rm growth impact difficult comp growth expect brains-on-lin kw biotest mpi research acquisit off-set divestitur contribut growth close mpi research expect contribut million revenu model guidanc revenu growth tailwind fx eign exchang guidanc set base bank forecast forward fx rate compar assum fx rate euro pound usd depreci growth expect organ growth net tailwind acquisit fx margin adj earn charl river rais long-term margin target dsa manufactur lt margin target includ rm dsa manufactur total compani goal consolid oper margin manag expect see modest improv oper margin improv earli close charl river expect accret mpi research embed guidanc vc gain excess tax benefit associ stock-bas comp tax rate mm charl river guid cffo rang million estim million repres growth mm uptick capital-expenditure due capac invest rm china biolog safeti assess well invest leveragefollow announc acquisit mpi research would expect compani focu debt repay tuck-in near-term compani intend repurchas share charl river goal exit net debt-to-ttm ebitda ratio statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ charl river
biggest beneficiari biopharma wave given
leadership posit earli stage drug
discoveri research said view thesi
balanc today valuat line
charl river continu benefit favor
safeti assess compani push price
expand capac drive upsid growth
upsid case repres upsid
ebitda million
charl river exposur earli stage biopharma
research make expos fund activ dis-
leverag safeti assess busi would lead
earn compress given fix cost
downsid case repres downsid
ebitda million
recent thought agil
pleas see report
takeaway barclay
continu caution around genom health invest thesi head
competit biggest concern view myriad market entri march
substanti differ prior threat given oncolog salesforc almost
individu coverag us payor endopredict addit compani
announc layoff earli march cautiou around potenti impact
revenu growth genom health guid revenu growth
midpoint million model toward lower end million
believ compani outlook emb number assumpt screen aggress
includ increment privat payor coverag prostat reimburs coverag
intern posit compani recent receiv posit lcd decis
assay partner epic scienc biggest opportun drive prostat
adopt medicar reimburs expans genom health
guid toward volum revenu growth though note traction
payor critic compani meet guidanc reiter underweight
rate price revenu estim million
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidanceinvas breast volum growthw believ oncotyp dx invas breast long-term lsd grower penetr us recent trend better due favor respons tailorx studi initi result competit repres threat myriad launch endopredict compani believ combin ajcc stage criteria began januari tailorx intermedi result asco june help acceler global growth volum growthgrowth prostat cancer prognost test remain opportun genom health receiv coverag decis favor intermedi risk patient octob genom health expect volum revenu growth expand privat payor reimburs nccn growthintern volum growthw forecast intern volum growth would mark deceler growth broad decis german gba expect later live guidanc also assum compani maintain coverag europ room grow revenuew model contirbut million growth begin genom health expect oncotyp dx receiv posit medicar coverag decis contribut growth rang million recent compani receiv favor lcd decis growthth compani longer issu test volum guidanc expect volum growth driven strength prostat intern well digit net revenu mm genom health guidanc impli revenu increas rev million impli growth midpoint specif expect growth driven ramp volum expand reimburs coverag increas medicar price oncotyp dx follow implement pama expect drive increment million revenu gross revenu guidanc million assum million bad ebitda mm compani guid million ebitda driven channel leverag intern growth us prostat statement barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight genom oper
genom test best known oncotyp dx
platform substanti revenu come
invas breast cancer prognosi despit
matur product market continu
gener neg margin ahead new product
launch see near-term opportun
remedi situat
genom health success execut
opportun dci prostat cancer
intern market see upsid share
reflect upsid revenu
competit threat core product emerg
new product launch face greater headwind
adopt expect see downsid share
reflect downsid revenu
thought holog
barclay
report
op hot miami
continu believ short-term focu disrupt cynosur
present attract entri point share believ compani
post aesthet result anywher close dec result million
substanti posit thesi march histor sequenti weaker aesthet
quarter given capit natur sale segment said expect
complet salesforc hire march greater product new product
repres sequenti tailwind result around million would provid platform
improv addit follow weaker result gyn surgic
trend busi import monitor earn good news
busi perform well recent channel check consist mqsa
data bode well breast health result diagnost good foot viral
load fusion recent approv final expect intern remain growth
engin next sever year continu view valuat compel
context consolid result msd top line double-digit ep busi
fundament reiter overweight rate
et wednesday may commentarybarcguidancebarcguidancebreast health organ growth model increas servic growth product revenu compani surpass penetr instal base tone around placement opp conserv said believ new instrument low high end help elast demand servic revenu remain signific opportun growth share gain convers cycl price premium expect lsd growth also driven affirm brevera growthdiagnost organ growth growth led mdx dx total model forecast assum deeper panther penetr expans well opportun expand menu viral load respiratori area fusion model increas cytolog perinat dx total growth expect million contribut blood screen busi growth ex blood screen gyn surgic organ growth model flat organ growth organ declin novasur growth myosur view conserv result organ weaker expect due difficult comp fewer sell day addit novasur result disappoint organ due increas competit weaker market environ endometri ablat result expect remain weak believ combin leadership chang updat salesforc incent new product novasur advanc myosur manual help stabil result aesthet revsseason expect off-set salesforc product improv contribut tempsur launch beyond view cynosur lt dd grower improv salesforc product new product launch consum growth cross-sel opportun improv convict sustain growth growth growth sale shown impress recent result dd organ growth last four quarter growth driven gain european breast health panther placement gyn surgic cynosur n/an/an/an/aorgan guidanc face headwind sell day growth lose day gain impact sell op margin model ebit margin due neg mix impact blood screen divestitur cynosur growth model net growth cynosur less blood screen acquisit fx expect tailwind tailwind earn updat ep guidanc due tax reform benefit compani expect tax rate previou expect plan reinvest half save lead ep benefit tax reform ttm leverag follow divestitur subsequ acquisit expect leverag net debt ebitda exit near-term focu repruchas outstand convert tuck-in repurchas opportun emb million debt repay mm free cash flow expect forecast repres revenu flat repurchas repres upsid stmtcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product launch
add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
thought icon
barclay healthcar
confer see report
 life
end market op hot
follow transit year icon expect organ growth infect
compani expect organ growth rang model
repres acceler guidanc base
icon believ repres less headwind growth due time
recognit reimburs expens better organ growth support strong net
book grew repres book-to-bil icon
continu expect custom concentr moder guidanc
impli declin y/i requir compani drive growth smaller
custom icon guid toward ep rang
model posit icon note repurchas million
share to-dat set appear sound remain cautiou
around valuat reiter equal weight rate
et thursday may commentarybarcguidancebarcguidancegross ordersgross award lumpi model growth impli growth greater outsourc market share gain manag note budget continu strong level outsourc increas gross order improv improv visibl revenu growth inflect elev level cancel cancel rate return normal level expect similar level cancel burn ratew model revenu burn decreas greater mix special trial drive decreas burn rate across cro industri expect icon burn rate stabil revenu expect gross revenu growth emb organ growth tailwind fx tailwind mapi acquisit icon updat revenu guidanc reflect adopt revenu recogn percentag complet method base project input addit compani report gross revenu inclus reimburs expens pass-through cost billionreimburs expensesthes revenu primarili consist fee paid investig site reimburs client treat pass-through zero margin expect reimburs expens grow y/i revenu expect net revenu growth growtha contribut compani largest client stabil expect organ revenu growth infect support strength recent book organ revenu growth target includ impact expect less headwind revenu growth driven time differ recognit pass-through simpli put reimburs expens grow slower rate net growthicon expect mapi close acquisit add growth emb tailwind mapi acquisit compani guid toward fx tailwind expect fx tailwind gross revenu growthdu time relat issu adopt forecast impact revenu growth less compar margin adj inc amort icon lead margin amongst driven compani effici manag workforc said manag still see upsid opportun sg enhanc result expect margin continu ramp revenu growth icon face optic headwind margin due adopt expect impact adopt forecast repres revenu upsid guidanc barclay healthcar confer icon repurchas million share to-dat averag price impli compani million million remain author statementcash industri view neutral
equal weight icon success
transit nich european cro
becom intern top-tier cro recent result
show compani grow expect
headwind largest custom said
think compani need activ data
integr industri lead margin also impli
less room upsid
icon exhibit signific growth margin
expans improv custom diversif
would improv sentiment icon futur prospect
upsid case repres
upsid ebitda million
revenu concentr could continu
repres headwind overal growth similarli
industri cancel issu could continu begin
weigh icon growth margin downsid
case repres downsid
ebitda million
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
thesi depend long-
maintain equal weight rate think quarter
non-ev revenu guid sequenti due
stock order time shipment note oddli wide spread
consensu ep estim analyst around analyst
includ thesi instal base continu
transit novaseq price point per gb lower hiseq hiseq
 revenu growth guidanc screen conserv
question whether consum growth continu moder critic valuat
model consum growth hand novaseq
placement healthi instal base exit compani
continu see multi-year upgrad cycl ahead novaseq note
high-throughput custom upgrad new platform far model
increment novaseq placement reiter ew rate continu
look greater convict long-term growth order justifi valuat
et tuesday april commentarybarcguidancebarcguidancenovaseq placement launch new high-throughput sequenc whole genom applic far feedback strong compani ship instrument forecast placement placement placement annual beyond model consum pull-through instal basewith introduct novaseq cannib hiseq hiseq placement begin custom recent purchas option upgrad novaseq target hiseq user first said compani expect multi-year transit hiseq custom order first novaseq end expect net hiseq remov instal base consum growth model consum growth inventori burndown hiseq famili off-set increas novaseq consum demand given uptick placement instrument growth instrument revenu expect sequenti consist previou year given typic season growtharray growth driven rise popular consum genom demand spike lower price point consum genom test expect growth slow comp becom growthour organ growth forecast emb slight acceler consum instrument growth guidanc top-lin growth y/i includ ramp consum instrument growth driven meaning novaseq revenu contribut revenu expect sequenti rev ex-comp expect continu compris signific portion budget forecast repres declin margin adj forecast oper margin increas y/i forecast oper margin flay guidanc includ benefit associ tax reform helix statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight leader next
gener sequenc market
project growth
posit fundament
impress compani abil transform
genom market believ sentiment well
reflect share
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ebitda billion
given pace innov cycl next
gener sequenc believ still
earli declar instrument choic
clinic use downsid case reflect
downsid ebitda million
pleas see report
mid-term target
believ critic year iqvia show acceler revenu growth
demonstr integr data strategi reson client
proof iqvia billion increment award result
differenti offer believ potenti disrupt strategi one sever
factor could drive recent uptick cro industri consolid
believ success reflect backlog growth new busi win start
uptick revenu first award combin offer
given iqvia issu long-term revenu growth guidanc msd would
expect initi guidanc conserv view compani drive
upsid target prove success strategi would posit
sentiment continu share repurchas remain author
execut synergi like use lever earn line
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidanc net auth ttm mm watch new award critic integr data strategi compani attribut billion award data end backlog forecast step-up net new author less revenue net book-to-bil ttm mm expect book-to-bil though quarterli result lumpi upsid driven market share gain believ merger integr risk subsid gross rev mm expect revenu growth emb fx organ gross revenu net rev mm net revenu growth expect includ organ net revenu gross revenu mm estim emb organ growth tailwind fx despit higher level new drug approv iqvia expect busi declin remind report june note compani evalu sale solut mm gross revenuesour revenu estim emb tailwind fx net tailwind acquisit organ growth juli compani sold encor busi drag growth revenueund revenu recogn percentag complet method base project input addit compani report gross revenu inclus reimburs expens pass-through growth forecast gross organ growth solut declin integr engag servic growth commerci solut forecast gross organ growth solut declin integr engag servic growth commerci solut assum rate believ iqvia expect fx tailwind roughli gross revenu growth gross revenu growth estim includ tailwind fx contribut marginexpect cost synergi run-rat million ebitda margin optic reduc chang ep anticip earn growth lead cash ep iqvia expect non-gaap tax rate capital-expenditure forecast repres increas buy-back author februari remain current author ep guidanc assum continu compani share repurchas program statement industri view neutral
overweight believ iqvia creat
best class platform cro industri believ
marri quintil cro platform im clinic
insight yield market share gain time
earn growth
believ iqvia valu proposit could yield
market share gain time coupl long
runway cost synergi upsid case
repres upsid adj ebitda
risk around integr recent growth
trend integr engag solut
busi could weigh near-term growth
downsid case repres downsid
adj ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
view labcorp
posit evolv
healthcar industri see
report see
global
thought labcorp
barclay
report
op hot miami
believ short-term caution thesi relat weather
model ep street volum headwind said
believ covanc could surpris upsid easi comp final
import debat thesi upcom payor renew
aetna believ open network quest labcorp would
strateg posit nation lab diagnost rev expect
underli trend remain strong model volum growth driven
recent lab acquisit underli util off-set inclement
weather comp revenue-per-req despit deflationari price pama
expect improv driven posit mix toward genom
esoter test better fx covanc rev industri lead book
help improv visibl businesss expect organ revenu growth ramp
believ execut covanc launchpad save
allow margin expans deflationari price environ pama labcorp
top pick believ valuat compel ebitda
et wednesday april commentarybarcguidancebarcguidancelcd volum model organ volum aid acquir volum organ includ underli util weather due winter storm northeast model organ volum acquir volum organ includ util weather easier hurrican comp partial off-set winter pricefast growth genomic/esoter test push price higher notabl expect pama headwind total rev-per-req lab busi offset mix benefit price result flat organ price fx expect tailwind price organ adj op margin bad debt net revenu optic tailwind margin adjust account chang estim margin help off-set impact pama labcorp believ on-going save opportun lcd segment move forward net book-to-billcov post industry-lead book-to-bil stronger book bode well revenu growth book forecast base net revenu organ growthstrong book support revenu inflect covanc year compani expect organ growth mid-to high-single-digit organ growth guidanc base gross revenu report restat gross revenu remind covanc lap larg clinic trial cancel central lab busi improv comp adj op margin labcorp recent announc covanc launchpad initi compani aim gener million cost save cro busi remind compani achiev million save program believ cost save initi import lever help off-set neg margin impact pama margin optic lower adopt organ growthorgan growth guidanc base revenu compani restat revenu segment expect organ growth covanc diagnost segment guid toward tailwind fx anticip fx tailwind growth emb contribut chiltern mt sinai paml transact transact expect contribut growth ep assum cut medicar revenu lab revenu anticip pama roughli headwind ep mm follow activ year would expect labcorp priorit debt repay near term repurchas embed guidanc compani million share remain share repurchas author mm compani expect free cash flow rang million mm labcorp guid capital-expenditure revenu base statementcash barclay life scienc tool diagnost
laboratori corp america hldg lh
overweight labcorp remark track
record execut led lead organ
growth augment value-enhanc
acquisit covanc acquisit continu
theme expect expertis
organ posit labcorp premier
partner choic companion diagnost play
greater role clinic decis make
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceelr revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ebitda billion
pleas see report
consist compound
rich multipl initi equal
lab industri end market remain healthi level expect
organ growth deceler tougher comp within lab segment compani
specif see strength biopharma custom total revenu
addit china continu strongest market growth given
continu pent demand especi industri product follow solid
rais top bottom line guidanc modestli account quarterli beat
favor fx environ model organ growth
deceler compani note end market remain
strong caution remain limit room improv howev better
expect growth end market could drive upsid stock ultim
believ revers peer-level organ growth could pressur peer-lead valuat
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancelab organ growthth lab segment hsd grower last year strong demand biopharma custom compani continu view biopharma market attract expect biopharma custom reduc spend recent heighten level respons forecast good growth lab busi growth industri organ growthwith robust growth china core industri rebound follow slower growth previou year posit optimisit industri envrionemnt us europ within china question remain extent remain pent-up demand compani forecast msd growth segment growth product inspect organ growthproduct inspect demand remain strong given rise standard food qualiti around world domin player market share next competitor emerg market present opportun strong growth compani face challeng comp china particularli begin year said guid msd growth growth food retail organ growthresult volatil includ organ declin segment meaning slower growth segment compani manag profit growth growth china organ growthchina continu strongest market meaning growth across product line specif benefit shift resourc faster grow area chines demand continu robust compani guid solid follow mroe challeng comp growthw forecast normal organ growth expect serv tailwind tailwind growthth biotix acquisit expect contribut growth margin adj guid oper margin improv along benefit currenc margin expans driven organ growth price suppli chain initi annual price increas roughli better tool rais ep guidanc midpoint due solid result favor fx environ forecast buy-back statementcash barclay life scienc tool diagnost
equal weight market leader
precis weigh analyt instrument
compani dispar custom base allow
differenti unit price time consist free
cash flow deploy toward tuck-in
share repurchas biggest near-term risk
relat valuat share screen rich
opinion
better execut end market perform drive
upsid ebitda forecast re-rat
ev/ebitda multipl gener upsid
case
macro pressur end market perform drive
downsid ebitda forecast
valuat re-rat ev/ebitda multipl
gener downsid case
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
thought riskscor
pleas see
volum adopt
thought genesight
pleas see
posit neg full
data set critic may
guidanc screen conserv front myriad thesi
highli depend upcom public genesight rct studi early-
may confer biggest opportun quarter coverag expans cdx
metastat breast cancer open preval pool increment annual
incid pool test addit myriad focus drive hct volum
riskscor launch substanti opportun prevent test final believ
medicar price increas pama prolari vectra da well expand
medicar coverag prolari endopredict improv visibl revenu growth
second half year said maintain equal weight rate myriad
believ reimburs coverag new product critic justifi
acceler earn growth valuat model ep acceler
base case
model assum measur ramp reimburs coverag time though
arduou process payor negoti reduc visibl achiev ramp
ultim need convict manag care reimburs new product
order justifi valuat thesi
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancehct revenu model revenu declin y/i genesight revenu mm myriad shown impress volum growth genesight penetr psych channel model pro-forma volum growth moder larg number growth primari driver pro-forma revenu growth revenu mm favor intermedi risk medicar coverag began septemb believ could act catalyst addit commerci payor coverag model price increas reflect increas medicar rate expect prolari volum increas addit payor upsid could come nccn updat da revenu mm volum decreas sequenti though improv y/i stabil salesforc expect volum revenu improv model increas price new medicar rate myriad could see addit upsid vectra includ american colleg rheumatolog acr revenu mm outsid product describ endopredict repres notabl opportun myriad establish coverag payor growth model organ declin includ declin growth genesight contribut quarter acquir growth margin adj payor coverag top line leverag critic improv elev initi expect gener million save includ million forecast oper margin expans ratea result tax reform compani lower tax rate guidanc myriad increas ep guidanc midpoint increas attribut increas strength busi environ tie benefit tax reform compani priorit debt repay near-term use cash myriad expect fulli paid balanc credit facil end said manag indic would buy-back share statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight
crossroad look manag
competit concern hereditari cancer test
drive growth new product view
thesi balanc point
expect revenu acceler new product
launch carri greater increment margin
commerci upsid case
reflect upsid ep
myriad face new competit hereditari
cancer test commerci new product
face rigor review payor downsid
case reflect multipl downsid
ep
continu balanc achiev long-term target rel valuat
issu discoveri analyt solut da tool segment
diagnost given lack production/manufactur asset drive growth
peer post improv result includ organ growth
focu euroimmun given signific ramp revenu
throughout year model rev year specif
struggl model compani view hsd long-term organ revenu growth
thereaft op margin
rel differenti lack biopharma product
asset peer drive excess growth addit core industri exposur isnt
differenti catch outsiz tailwind global recoveri lean
emerg market diagnost avenu drive better perform ultim
view share fulli valu trade ebitda estim cautiou
et monday april commentarybarcguidancebarcguidancediagnost organ growthgrowth expect driven screen busi includ newborn infecti diseas test well compani recent announc genet initi emerg market strong end market expect drive faster long-term growth tulip acquisit increas exposur india follow acquisit euroimmun close compani presenc autoimmun allergi diagnost em analyt solut da organ growth expect recent improv industri academ end market continu food safeti expect acceler tailwind increas regul china manag anticip slowdown biopharma market though growth broadli lag tool peer growthour forecast impli improv anticip fx serv tailwind growth complet sale medic imag busi may addit compani complet acquisit tulip diagnost euroimmun acquisit close decemb expect add million revenu overal model acquir growth margin adj target oper margin nearer term compani expect expand oper margin ratequidel guid tax rate epsepg guidanc includ euroimmun cffo mm expect continu pay quarterli dividend per mm follow euroimmun acquisit continu prefer bolt-on acquisit follow share repurchas debt paydown statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight compel
portfolio nich product across environment
human health long-term outlook
organ growth margin improv
compel believ share
range-bound near term get better
visibl emerg market revenu
opportun china nucleic acid test
newborn screen drive upsid
ebitda forecast upsid ebitda
million yield upsid case
emerg market fx remain pressur drive
downsid estim
downsid ebitda million yield downsid
case
pleas see report
pleas see initi
growth data initi
believ investor cautious around health relat recent wsj
announc takeda pursu acquisit shire given
takeda import strateg partner view short-sight
potenti deal could posit long-term valu partnership result
larger overal budget takeda strong recent net new busi award
improv visibl target addit recent strateg
partnership notabl takeda announc partnership expect
continu increment contribut health offer
differenti growth profil among public cro group expect compani
drive upsid organ revenu growth guidanc throughout view
symphoni health transact close strateg sound way
improv compani data valu proposit expect updat focu
integr context compani industry-lead growth profil view
valuat attract ebitda reiter overweight rate
et thursday april press releas close april commentarybarcguidancebarcguidancegross order model gross order growth project growth emb growth greater outsourc market share gain look back abl consist outgrow peer anticip cancel rate higher rate due repriorit larg client due conserv backlog methodolog compani book cancel said busi could return burn ratea clinic trial becom increasingli complex revenu burn rate decreas across cro industri model burn rate y/i model y/i gross rev mm revenu recogn percentag complet method base project input addit compani report gross revenu inclus reimburs expens pass-through cost gross revenu growth emb reimburs expens growth net revenu growth research net rev mm clinic research net revenu estim emb organ growth tailwind solut revenu mm data solut busi compris acquir symphoni busi close guid low-teen growth pro-forma basi growth net organ growthw believ strong recent busi award improv visibl near-term double-digit revenu growth without repriorit organ growth would higher growthth symphoni acquisit contribut acquir growth partial acquir contribut net revenu growth expect model fx tailwind respect usd revenu exposur cost exposur guidanc assum euro pound exchang rate respect growth expect growth emb fx tailwind tailwind acquir growth net organ growth expect growth emb fx tailwind tailwind acquir growth net organ growth ep expect non-gaap tax rate expect impact ep capital-expenditure forecast repres gross would expect focu debt repay near term flowincom statement barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight health lead cro
focus late stage clinic develop
believ approach data util clinic trial
posit well increas demand
biopharma sponsor augment recent
acquisit symphoni health view valuat
attract context health market-
combin better clinic research growth
augment new data capabl drive
upsid ebitda forecast upsid case
repres upsid ebitda
weaker growth matur strateg partnership
could limit upsid organ growth margin
expans downsid case repres
downsid ebitda million
thought labcorp
barclay
report
op hot miami
believ set solid compani growth driver continu
becom larger part portfolio headwind shrink notabl qiagen
highlight ngs-relat revenu step-up y/i ad
growth high convict quantiferon-tb sustain growth
aid new relationship diasorin uncov ad growth
model establish goal addit qiasymphoni placement
believ double-digit growth relat consum contribut
growth new cdx relationship fda approv support growth
person medicin ad bp growth offset factor
headwind us hpv exit overal sale model organ
growth overal compani believ could prove conserv given
factor solid end market fundament base sampl prep franchis qiagen
differenti busi mix almost recur revenu exposur
growth person medicin continu favor overweight
rate believ execut compani organ revenu growth ramp
margin improv target justifi premium valuat stock
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancequantiferon growth rev quantiferon continu grow cer driven convers legaci tst test support guidelin cdc uspstf launch gen test target revenue long-term expect quantiferon grow symphoni base rev expand instal base drive consum growth placement opp benefit continu expans menu abroad us system found nich custom run ldt annual pull-through per instrument roughli place roughli instrument expect generead modestli contribut organ growth estim annual pull-through per instrument compani includ formal guidanc placement long term goal market share benchtop total revenu expect grow growth emb growth academ growth mdx pharma appli forecast growth academ growth mdx growth pharma growth appli mdx growth driven quantiferon qiasymphoni generead overal end market demand compani sampl prep portfolio fx compani guid toward fx tailwind revenu tailwind ep compani expect fx tailwind revenu growth divest growthin emb headwind recent china mdx divestitur remind exiqon omicsoft acquisit annual china mdx divestitur expect headwind stat-dx acquisit expect contribut million growth ebit margin compani optimist restructur activ contribut oper margin improv anticip improv ep expect non-gaap tax rate versu previou guidanc adjust ep includ contribut stat-dx benefit share repurchas forecast impli revenu mm earn announc million share repurchas program expect complet program expect add ep statement barclay life scienc tool diagnost
overweight reach inflect
point serv baselin
acceler growth molecular diagnost look
forward leadership companion
diagnost develop next gener
sequenc capabl give us visibl
million near-term revenu opportun
number avenu growth
give investor better visibl revenu growth
upsid case reflect upsid
ep
price competit diagnost pressur
result estim come guidanc
expect downsid case reflect
downsid ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
focu w/ solid
believ sentiment quest cautiou pertain inclement weather
model ep consensu beyond quarter key focu
industri consolid reimburs pressur pama impact long-
term ep growth point remain cautiou earn growth
trajectori ep growth includ pama headwind thesi
depend peer consolid hit long-term target mid-to-high singl
digit earn growth watch trend close inflect hospit
outsourc recent announc contribut earlier deal put quest
good foot exceed acquir growth along tax reform
help off-set pama headwind near term underli lab volum
stronger recent histori driven growth genom test
forecast volum growth organ acquir growth
cautiou around weather sever storm impact northeast
 quest exposur peer model headwind
et thursday april commentarybarcguidancebarcguidancevolum forecast includ organ declin acquisit peacehealth outreach fusion/clearpoint cchc hartford healthcar cla cleveland heartlab shiel xm within organ growth model underli util headwind weather benefit pl peacehealth forecast includ organ acquir growth organ model util new busi tailwind easier comp hurrican harvey/irma partial off-set sever weather per requisitionunderli rev-per-req posit driven mix faster growth genomic/esoter test outsid icar expect unit cost remain headwind notabl expect pama headwind total rev-per-req partial offset mix benefit organ growthlong-term guidanc assum equival growth includ pl arrang growthquest lt guidanc assum acquir growth annual carry-ov acquisit put quest good foot hit target growthlong-term guidanc assum revenu growth compound-annual-growth-rate emb organ growth acquisit guidanc includ tailwind un-announc lab acquisit despit upcom headwind pama quest remain commit long-term target compani guidanc estim base adopt revenu restat margin ex-amort margin improv optic due impact bad debt net revenu quest work optum number initi includ reduc paper requisit manag bad debt effici compani also focus greater autom site consolid go quest believ on-going opportun improv effici ex-amort assum cut icar revenu total anticip pama roughli headwind ep context pama quest guid ep rang quest guid tax rate plan reinvest portion save lower tax rate expect benefit ep mm quest expect lower tax rate benefit cffo million mm capital-expenditure expect step due million project relat construct new lab nj increas per share mm quest million remain current share repurchas author quest continu plan return major free cash flow sharehold form repurchas buyback emb repurchas statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight thesi quest rel
balanc compani financi flexibl
leverag scale deploy capit peer
said quest may need play catch-up
strateg integr solut across
clinic research clinic test
deploy capit better-than-expect
margin improv would repres upsid
estim upsid case reflect
upsid ebitda billion
reimburs headwind congression
action oner clinic lab hospit
penetr esoter test volum increas
downsid case reflect downsid ebitda
detail
pleas see analyst day
preview april
compel valu
pleas see analyst day
review april
believ set-up favor earn though quarter
somewhat de-risk given recent posit updat compani analyst day
specif manag note flu expect exceed million
given strong season coupl share gain sofia platform instal
base cardiovascular immunoassay expect deliv normal quarter around
million consist forecast look expect manag
reiter long-term potenti franchis attract point-of-car poc
market fundament new product potenti opportun drive
aspir revenu target billion would repres potenti
doubl busi year includ least high-singl digit organ growth
remain excit potenti redesign savanna molecular mdx poc
platform believ could meaning launch compani execut
new product synergi import drive cash ebitda margin
year final look updat path achiev leverag
end continu believ share great valu profit
strateg growth reiter overweight rate
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancecardiovascular immuno mm expect million line model model revenu contribut expect flat growth ramp millionflu revenu mm flu season track well previou year flu season guid toward flu revenu million prior year quarter infecti diseas mm similar flu infecti diseas product season respiratori season expect growth y/i driven strength strep dx mm anticip molecular revenu million nine fda approv solana assay model million molecular revenu includ savanna millionsofia instal base expect sofia instrument place end fda reclassif influenza test system class ii devic facilit share gain time believ address opportun could big revenueour revenu estim assum sever flu season compar assum normal flu season expect gener total revenu growth influenza growth primari driver due sever flu season growth close acquisit triage/bnp asset compani get roughli three quarter contribut expect million addit annual acquir revenu growthin manag guid toward double-digit growth legaci busi low-single-digit growth bnp/triag th compani analyst day guid toward high-singl digit organ revenu growth ebitda margin previous set lt target cash ebitda margin driven new product growth leverag overhead expens complet notabl project follow acquisit triage/bnp expect hit target compani april analyst day updat long-term margin target rateund tax reform expect non-gaap tax rate repurchasew expect cash flow gener focu debt repay follow triage/bnp deal expect exit leverag ratio statement barclay life scienc tool diagnost
overweight lead innov
point care poc test compani
leverag strength rapid infecti diseas
test build broader-bas diagnost platform
excit potenti sofia
penetr low-volum account also provid
compel solut address retail poc market
new product launch allow grow
market infecti diseas test take share
compani abl leverag infrastructur drive
synergi triag acquisit see upsid
share reflect upsid cash ep
risk pertain new molecular entrant
potenti take market share
infecti diseas test see downsid share
reflect downsid cash ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
thought syneo
barclay
report
op hot miami
remain cautiou syneo health head believ guidanc
updat lead reset expect earn result
manag opin adopt would lead reduct revenu
without meaning off-set cost remind adopt new account
standard chang revenu time near term reset ebitda pressur
syneo multipl pro-forma leverag forecast cash ebitda million
vs manag guidanc million beyond
await better visibl driver organ growth acceler back peer level
market focus earli integr trend follow merger inc research
inventiv health recent manag turnov elev leverag net debt
ebitda leav littl flexibl error said remain intrigu mani part
thesi believ valu integr offer clinic commerci
solut reiter equal weight rate
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancenet busi winswhil recent revenu growth compani clinic segment weaker histor trend compani new busi award solid syneo health achiev book-to-bil forecast step-up net new author less clinic revenue burn ratea clinic trial becom increasingli complex revenu burn rate decreas across cro industri model burn rate y/i model y/i slow compani burn rate revenu growth headwind organ growth health expect growth clinic busi estim fx tailwind model organ growth model total growth consist organ growth tailwind fx organ growth weaker year syneo commerci segment organ revenu growth weak driven lower level drug approv cancel smaller cancel reduc spend largest advertis client due robust pipelin syneo health posit commerci outlook rang expect declin organ declin off-set fx organ growth forecast organ growth clinic declin commerci organ growth target includ organ growth clinic growth commerci model tailwind fx line guidanc growth growth estim emb organ declin off-set benefit fx marginwith earn syneo health rais synergi target compani expect cost synergi run-rat run-rat compani laid upsid case optic headwind margin also econom impact headwind revenu due movement input base method epsw emb model expect repres modest headwind earn headwind revenu capital-expenditure forecast repres net debt-to-ttm ebitda expect syneo focu free cash flow debt repay near-term leverag compani abil use capit deploy meaning lever emb share repurchas model syneo health author new million buy-back program began march flowincom statement barclay life scienc tool diagnost
equal weight inc research inventiv
third largest cro largest provid commerci
solut merger creat opportun
complement offer two organ
drive revenu synergi said cautiou
around pro-forma leverag ttm ebitda
recent weak commerci solut
combin better commerci solut
segment growth cross-sel synergi drive
upsid ebitda forecast upsid case
repres upsid ebitda
oper execut merger integr
pressur new busi award earn growth
commerci solut segment
prolong weak downsid case
repres downsid ebitda million
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
thought thermo
fisher barclay
report
op hot miami
believ thermo fisher carri signific momentum see upsid
guidanc organ acquir growth manag guid organ
growth cours follow organ growth
best result among peer posit believ posit order growth commentari
improv convict near-term momentum fundament thermo fisher benefit
uniqu capabl biopharma across bioproduct clinic trial logist
recent acquir patheon busi macro datapoint suggest industri end
market remain healthi provid anoth lever growth final strong flu season
benefit growth season product margin ad
convers earli time headwind coverag reflect
guidanc acquir growth remain bullish patheon acquisit see
long runway ahead thermo fisher aggreg share wallet biopharma
custom reiter ow rate recommend share high-qual avenu
gain exposur theme innov healthcar
et wednesday april passcod n/ametricjack commentarybarcguidebarcguideorgan growthw believ manag guidanc organ growth could prove conserv given end market momentum season product off-set earli scienc solut lss believ thermo fisher hit stride life scienc solut broad-bas growth within segment compani optimist short long term prospect bioproduct believ benefit strong macro tailwind term visibl compani believ bioscienc segment rev better lead indic bioproduct book continu strong model growth growth full year instrument ai see opportun upsid ai segment industri exposur coverag seen posit order trend sinc model organ growth top tough comp notabl fei co enter organ growth calcul addit overal dx sd believ sd continu rel laggard model organ growth repres acceler product servic lp strong growth driven sale channel clinic trial logist model organ growth versu model organ growth expect patheon contribut fisher expect fx million revenu tailwind growthour forecast emb acquir growth partial year close finess informat patheon margin adj forecast expans emb dilut patheon lower oper margin guidanc impli growth mm forecast reflect increas forecast repres revenu mm compani increas dividend plan return million sharehold dividend repurchas mm compani guid million repurchas expect complet statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight thermo fisher market leader
across divers portfolio life scienc tool
diagnost impress global reach across
custom class end market compani
consist track record organ growth capit
deploy manag execut
recommend share core hold exposur
innov healthcar
see upsid thermo fisher target
capit deploy better result
life acquisit upsid case reflect
upsid ebitda billion
thermo fisher exposur econom activ
end market could impact growth
downsid case reflect downsid
ebitda billion
believ underli demand driver across end market product
famili remain consist import updat quarter includ activ
compani execut repurchas debt paydown given substanti benefit
repatri end market tracker biopharma revenu demand
appear strong leadership posit lc carri sticki recur revenu
addit expect china continu notabl contributor growth
countri look establish greater life scienc presenc adopt western technolog
overal view organ growth guidanc reason tax reform
expect serv headwind compani tax rate view net
posit allow better access oversea cash
increas flexibl use oversea cash may provid upsid number
compani execut repurchas debt paydown
et tuesday april commentarybarcguidancebarcguidancebiopharma organ growthbiopharma lead growth driver given compani strength lc growth tie increas global pill count well larger popul access therapeut posit routin workflow qa/qc innov larger more-complex molecul drive demand character also benefit govern organ growth struggl rebound academ govern follow quarter cite broad geograph strength rel peer compani exposur high-end instrument segment academ market thu great read rest coverag model growth given tough organ growthrevenu tend lumpi grow ex-fx expect segment continu driven demand food industri end market manag expect continu stabl demand compani well-posit cyclic asia continu major growth driver growth driven strong result china asia largest geograph region term revenu benefit rise standard regul qualiti pharma healthcar appli set china revenu mix pharma food instrument instrument sale lumpi instrument revenu grew organ basi benefit leadership lc well success new product launch instrument growth import indic futur consum servic organ growthopt impact one addit workday extra day growthdur march investor day laid forecast mid-singl digit organ growth margin adj oper expens expect grow rate slower sale growth model expans compani oper margin alreadi highest amongst tool expect fx neutral impact ep ep estim impli growth tax reform place compani main capit deploy prioriti remain invest mm compani pay assum share count million share buyback expect off-set neg impact tax reform statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight admir track
record above-market revenu growth margin
given compani market domin
pharmaceut custom chromatographi
said balanc water success view
difficult gener sustain above-
market earn growth reflect
biopharma remain area strength higher
consum margin drive upsid
ebitda expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid
ebitda estim downsid ebitda
million yield downsid case
valuat methodolog risk
laboratori corp america hldg lh
valuat methodolog price target repres ebitda estim billion
risk may imped achiev barclay research valuat price consider uncertainti around
protect access medicar act pama could impact reimburs clinic lab start nearer term expect
reimburs continu remain pressur least inflationari physician consolid could drive lab market share
valuat methodolog price target repres ebitda estim billion
risk may imped achiev barclay research valuat price consider uncertainti around
protect access medicar act pama could impact reimburs clinic lab start nearer term expect
reimburs continu pressur least inflat physician consolid could drive lab market share toward
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
